Loading clinical trials...

A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment | Clinical Trials | Clareo Health

COMPLETED

A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment

An Observational, Prospective, Multicentre Study to Assess the Sensitivity to Change of the SAMANTA Questionnaire in Women with Heavy Menstrual Bleeding (HMB)

NCT03751800•Bayer

View on ClinicalTrials.gov

Summary

A study run at multiple study sites in Spain to test whether the SAMANTA questionnaire that is used to diagnose heavy menstrual bleeding (HMB), can also be used to assess changes of severity of HMB in women with HMB who are treated during 12 months with a chronic hormonal treatment. Patients that are treated with chronic hormonal treatment as Levonorgestrel (trade name Mirena) or with a combination of estradiol valerate and dienogest (trade name Qlaira) or with Medroxyprogesterone acetate (trade name Progevera) and any new hormonal treatment marketed in Spain that has the indication for HMB in routine gynaecological practice are observed for 12 months in this study or for a shorter period in time in case of withdrawal. The study aims also to describe the overall satisfaction of women with their chronic hormonal treatment for HMB and how the women think their menstrual bleeding has changed. In addition the study aims to describe the changes of the score that is derived from the SAMANTA questionnaire in relation to Quality of Life. Quality of Life is measured with the SF36v2 questionnaire. The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Women in childbearing age, ≥18 years old, not intending to become pregnant during the next year.
•Women diagnosed with heavy menstrual bleeding or idiopathic menorrhagia according to medical criteria and based on clinical judgment.
•Women for whom the clinician decides, in agreement with the patient, to prescribe any of the available chronic hormonal treatments with the therapeutic indication of HMB in Spain (Mirena, Qlaira or Progevera).
•Women capable of reading and writing.
•Women who signed the informed consent.

Exclusion Criteria

•Women with amenorrhea or menopause.
•Women with contraindications and warnings with the chronic hormonal treatment prescribed for HMB as per the summary of product characteristics (interaction with concomitant medication, etc.).
•Women receiving contraceptive hormonal therapy or using a copper intrauterine device.
•Women on hormone replacement therapy.
•Women with a history of malignancy.
•Women with degenerative diseases that could directly negatively impact their daily life.
•Women who have given birth within the previous 6 months.
•Women who are pregnant.
•Women participating in an investigational program with interventions outside of routine clinical practice.
•Women with psychiatric disorders who are unable to make decisions and follow instructions.
+1 more criteria

Locations (1)

Many locations

Many Locations, Spain

Key Dates

Start Date

December 12, 2018

Primary Completion Date

March 12, 2021

Completion Date

May 18, 2021

Last Updated

October 18, 2024

Enrollment

422

ACTUAL participants

Conditions

Menorrhagia

Interventions

Chronic hormonal treatment

DRUG

Effects of Resistance Training Intensity on Cardiovascular Parameters of Hypertensive Women

NCT06538454

Arterial HypertensionPostmenopausal; Menorrhagia+1 more

View study

COMPLETEDNA

Efficiency of Lina LibrataTM System

NCT03670680

Menorrhagia

View study

WITHDRAWN

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment

Inclusion Criteria

Exclusion Criteria

Effects of Resistance Training Intensity on Cardiovascular Parameters of Hypertensive Women

Efficiency of Lina LibrataTM System

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

Prevalence and Impact on Quality of Life, Academic Performance, and Blood Indices of Heavy Menstrual Bleeding Among Female Students in Assiut University, Egypt

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

Post Approval NovaSure Essure Labeling Study